Metabolomics in asthma

Bruce A. Luxon

    Research output: Chapter in Book/Report/Conference proceedingChapter

    8 Citations (Scopus)

    Abstract

    Asthma and airway inflammation are responses to infectious stimuli and the mechanisms of how they are mediated, whether by the innate or adaptive immune response systems, are complex and results in a broad spectrum of possible metabolic products. In principle, a syndrome such as asthma should have a characteristic temporal-spatial metabolic signature indicative of its current state and the constituents that caused it. Generally, the term metabolomics refers to the quantitative analysis of sets of small compounds from biological samples with molecular masses less than 1 kDa so unambiguous identification can be difficult and usually requires sophisticated instrumentation. The practical success of clinical metabolomics will largely hinge on a few key issues such as the ability to capture a readily available biofluid that can be analyzed to identify metabolite biomarkers with the required sensitivity and specificity in a cost-effective manner in a clinical setting. In this chapter, we review the current state of the metabolomics of asthma and airway inflammation with a focus on the different methods and instrumentation being used for the discovery of biomarkers in research and their future translation into the clinic as diagnostic aids for the choice of patient-specific therapies.

    Original languageEnglish (US)
    Title of host publicationAdvances in Experimental Medicine and Biology
    PublisherSpringer New York LLC
    Pages207-220
    Number of pages14
    Volume795
    ISBN (Print)9781461486022
    DOIs
    StatePublished - 2014

    Publication series

    NameAdvances in Experimental Medicine and Biology
    Volume795
    ISSN (Print)00652598

    Fingerprint

    Metabolomics
    Asthma
    Biomarkers
    Inflammation
    Molecular mass
    Adaptive Immunity
    Hinges
    Metabolites
    Innate Immunity
    Immune System
    Costs and Cost Analysis
    Sensitivity and Specificity
    Chemical analysis
    Research
    Costs
    Therapeutics

    ASJC Scopus subject areas

    • Biochemistry, Genetics and Molecular Biology(all)
    • Medicine(all)

    Cite this

    Luxon, B. A. (2014). Metabolomics in asthma. In Advances in Experimental Medicine and Biology (Vol. 795, pp. 207-220). (Advances in Experimental Medicine and Biology; Vol. 795). Springer New York LLC. https://doi.org/10.1007/978-1-4614-8603-9_13

    Metabolomics in asthma. / Luxon, Bruce A.

    Advances in Experimental Medicine and Biology. Vol. 795 Springer New York LLC, 2014. p. 207-220 (Advances in Experimental Medicine and Biology; Vol. 795).

    Research output: Chapter in Book/Report/Conference proceedingChapter

    Luxon, BA 2014, Metabolomics in asthma. in Advances in Experimental Medicine and Biology. vol. 795, Advances in Experimental Medicine and Biology, vol. 795, Springer New York LLC, pp. 207-220. https://doi.org/10.1007/978-1-4614-8603-9_13
    Luxon BA. Metabolomics in asthma. In Advances in Experimental Medicine and Biology. Vol. 795. Springer New York LLC. 2014. p. 207-220. (Advances in Experimental Medicine and Biology). https://doi.org/10.1007/978-1-4614-8603-9_13
    Luxon, Bruce A. / Metabolomics in asthma. Advances in Experimental Medicine and Biology. Vol. 795 Springer New York LLC, 2014. pp. 207-220 (Advances in Experimental Medicine and Biology).
    @inbook{5ddaf8440e3c40a48eb63609b939901b,
    title = "Metabolomics in asthma",
    abstract = "Asthma and airway inflammation are responses to infectious stimuli and the mechanisms of how they are mediated, whether by the innate or adaptive immune response systems, are complex and results in a broad spectrum of possible metabolic products. In principle, a syndrome such as asthma should have a characteristic temporal-spatial metabolic signature indicative of its current state and the constituents that caused it. Generally, the term metabolomics refers to the quantitative analysis of sets of small compounds from biological samples with molecular masses less than 1 kDa so unambiguous identification can be difficult and usually requires sophisticated instrumentation. The practical success of clinical metabolomics will largely hinge on a few key issues such as the ability to capture a readily available biofluid that can be analyzed to identify metabolite biomarkers with the required sensitivity and specificity in a cost-effective manner in a clinical setting. In this chapter, we review the current state of the metabolomics of asthma and airway inflammation with a focus on the different methods and instrumentation being used for the discovery of biomarkers in research and their future translation into the clinic as diagnostic aids for the choice of patient-specific therapies.",
    author = "Luxon, {Bruce A.}",
    year = "2014",
    doi = "10.1007/978-1-4614-8603-9_13",
    language = "English (US)",
    isbn = "9781461486022",
    volume = "795",
    series = "Advances in Experimental Medicine and Biology",
    publisher = "Springer New York LLC",
    pages = "207--220",
    booktitle = "Advances in Experimental Medicine and Biology",

    }

    TY - CHAP

    T1 - Metabolomics in asthma

    AU - Luxon, Bruce A.

    PY - 2014

    Y1 - 2014

    N2 - Asthma and airway inflammation are responses to infectious stimuli and the mechanisms of how they are mediated, whether by the innate or adaptive immune response systems, are complex and results in a broad spectrum of possible metabolic products. In principle, a syndrome such as asthma should have a characteristic temporal-spatial metabolic signature indicative of its current state and the constituents that caused it. Generally, the term metabolomics refers to the quantitative analysis of sets of small compounds from biological samples with molecular masses less than 1 kDa so unambiguous identification can be difficult and usually requires sophisticated instrumentation. The practical success of clinical metabolomics will largely hinge on a few key issues such as the ability to capture a readily available biofluid that can be analyzed to identify metabolite biomarkers with the required sensitivity and specificity in a cost-effective manner in a clinical setting. In this chapter, we review the current state of the metabolomics of asthma and airway inflammation with a focus on the different methods and instrumentation being used for the discovery of biomarkers in research and their future translation into the clinic as diagnostic aids for the choice of patient-specific therapies.

    AB - Asthma and airway inflammation are responses to infectious stimuli and the mechanisms of how they are mediated, whether by the innate or adaptive immune response systems, are complex and results in a broad spectrum of possible metabolic products. In principle, a syndrome such as asthma should have a characteristic temporal-spatial metabolic signature indicative of its current state and the constituents that caused it. Generally, the term metabolomics refers to the quantitative analysis of sets of small compounds from biological samples with molecular masses less than 1 kDa so unambiguous identification can be difficult and usually requires sophisticated instrumentation. The practical success of clinical metabolomics will largely hinge on a few key issues such as the ability to capture a readily available biofluid that can be analyzed to identify metabolite biomarkers with the required sensitivity and specificity in a cost-effective manner in a clinical setting. In this chapter, we review the current state of the metabolomics of asthma and airway inflammation with a focus on the different methods and instrumentation being used for the discovery of biomarkers in research and their future translation into the clinic as diagnostic aids for the choice of patient-specific therapies.

    UR - http://www.scopus.com/inward/record.url?scp=84934439823&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84934439823&partnerID=8YFLogxK

    U2 - 10.1007/978-1-4614-8603-9_13

    DO - 10.1007/978-1-4614-8603-9_13

    M3 - Chapter

    SN - 9781461486022

    VL - 795

    T3 - Advances in Experimental Medicine and Biology

    SP - 207

    EP - 220

    BT - Advances in Experimental Medicine and Biology

    PB - Springer New York LLC

    ER -